CA2263420A1 - Pharmaceutical compounds - Google Patents

Abstract

The invention provides novel cryptophycin compounds which can be useful for disrupting the microtubulin system, as anti-neoplastic agents, antifungal, and for the treatment of cancer. The invention further provides a formulation for administering the novel cryptophycin compounds.

Description

- W O 98/08506 PCTrUS97/1524 PHARMACEUTICAL COMPOUNDS
-This invention relates to the fields of pharmaceutical and organic chemistry and provides novel cryptophycin compounds useful as anti-microtubule agents.

Neoplastic disease, characterized by the proliferation of cells not subject to the normal control of cell growth, are a major cause of death in humans and other mammals. Clinical experience in cancer chemotherapy has demonstrated that new and more effective drugs are desirable to treat these diseases. Such clinical experience has also demonstrated that drugs which disrupt the microtubule system of the cytoskeleton can be effective in inhibiting the proliferation of neoplastic cells.
The microtubule system of eucaryotic cells is a major component of the cytoskeleton and is a dynamic assembly and disassembly. Thus, heterodimers of tubulin are polymerized and form microtubule. Microtubules play a key role in the regulation of cell architecture, metabolism, and division. The dynamic state of microtubules is critical to their normal function. With respect to cell division, tubulin is polymerized into microtubules that form the mitotic spindle.
The microtubules are then depolymerized when the mitotic spindle's use has been fulfilled. Accordingly, agents which disrupt the polymerization or depolymerization of microtubules, and thereby inhibit mitosis, comprise some of the most effective cancer chemotherapeutic agents in clinical use.
Additionally, the compounds claimed herein possess fungicidal properties. Further, such agents having the . ,. . . . , ,, . ,. " ~ ., . ,~ .. .

- W O 98/08506 PCT~US97/15245 ability to disrupt the microtubule system can be useful for research purposes.
Certain cryptophycin compounds are known in the literature; however, cryptophycin compounds having even greater solubility, robust potency are desired for most pharmaceutical uses and a broader library of cryptophycin compounds could provide additional treatment options.
Applicants have now discovered novel compounds providing such desired solubility as well as compounds having the ability to disrupt the microtubule system. Such compounds can be prepared using total synthetic methods and are, therefore, well suited for development as pharmaceutically useful agents.

The presently claimed invention provides novel compounds of Formula I

Ar~f ~Rl4 ~ ~ X ~ R

R Y ~ N O
Rl~ R7 R8 H
wherein Ar is phenyl or any simple unsubstituted or substituted aromatic or heteroaromatic group, ClC,2 alkyl, Cl-C,2 alkyne;
Rl is halogen, OH, oR3l, SH, amino, monoalkylamino, dialkylamino, trialkylammonium, alkylethio, dialkylsulfonium, sulfate, or phosphate;
R2 is OH, NH2, NR3l, SH; or R1 and R2 may be taken together to form an epoxide ring, an aziridine ring, an episulfide ring, a sulfate ring, a cyclopropyl ring, or monoalkylphosphate ring; or Rl and R2 may be taken together to form a second bond between Cl8 and Clg;

- W 098/08506 PCTrUS97/15245 R3l is Cl-C6 alkyl and hydrogen;
R3 is a lower alkyl group;
R4 is H;
R5 is Hi R4 and R5 may be taken together to form a second bond between C13 and Cl4;
R6 is a substituent selected from the group consisting of B-ring heteroaromatic, substituted heteroaromatic, B-ring ~CI-C6)alkyl, (C3-C8)cycloalkyl, substituted C3-C8 cycloalkyl, substituted (Cl-C6)alkyl, a group of the formula III':

p l ~
Rl7 III' and a group of the formula III'':

Z~

R III'';
R7 is selected from the group consisting of NR5'R52, R53NR51R52, oR53, H and a lower alkyl group; R51 and R52 are independently selected from the group consisting of Cl-C3 alkyl; R53 is Cl-C3 alkyl;
R8 is H or a lower alkyl group;
R7 and R8 can optionally form a cyclopropyl ring R9 is selected from the group consisting of H, a lower alkyl group, unsaturated lower alkyl, and lower alkyl-C3-C5 cycloalkyl;
R'~ is H or a lower alkyl group;
R9and R10 together optionally form a cyclopropyl ring;

CA 02263420 1999-02-ll - W O 98/08506 PCTrUS97/15245 R11 is selected from the group consisting of H, OH, simple ~alkyl, phenyl, substituted phenyl, benzyl, and substituted benzyl;
R'4 is ~ or a lower alkyl group;
Rl5, Rl6 and R17 are each independently selected from the group consisting of hydrogen, (C,-C6)alkyl, oR'8, halo, NR'8R19, NO2, OPO~H2, OR'9phenyl, SCH2phenyl, CONH2, CO2H, PO3H2, and So2R23, and ZZ;
Rla is selected from the group consisting of hydrogen, aryl, and Cl -C6 alkyl;
Rl8 is selected from the group consisting of hydrogen and (Cl-C6)alkyl;
Rl9 is Cl-C6 alkyl;
R~9 is selected from the group consisting of hydrogen and (C1-C6)alkyl R23 is selected from the group consisting of hydrogen and (C1-C3)alkyl;
R29 is (C1-C5)alkyl;
R30 is hydrogen or C~-C6 alkyl;
n is 0, 1, or 2;
p is 0, 1, or 2i m is 0, 1, or 2;
X is selected from the group consisting of 0, NH and alkylamino;
Y is selected from the group consisting of 0, NH, and alkylamino;
Z is selected from the group consisting of -(CH2) n~~ ~ (CH2)p-O-(CH2) m~ and (C3-C5) cycloalkyl;
ZZ is selected from the group consisting of an aromatic group and a substituted aromatic group; or a pharmaceutically acceptable salt or solvate thereof;
provided that when Rf is a group of Formula III' and n is 1, then at least one of the group consisting of Rl5, R16 and Rl7 must be a non-hydrogen group and if only one of R15, Rl6 and CA 02263420 1999-02-ll - W O 98~ C PCT~US97/15245 R17 is OH or oR29 and one of the group consisting of R15, rl6 ~ and R'7is halo then the remaining member of the group consisting of Rl5, Rl6, and R'7 must not be hydrogen or halo;
or when R6 is a group of Formu~a III' and n is 1, Rl4 is a lower alkyl group.
Further, the present invention provides compound of the formula I' Ar ~ O

~X R50 RllN~R
R Y ~ N O
R R R I' wherein Ar is phenyl or any simple unsubstituted or substituted aromatic or heteroaromatic group, C,-C,2 alkyl, Cl-CI2 alkyne;
Rl is halogen, OH, oR3', SH, amino, monoalkylamino, dialkylamino, trialkylammonium, alkylthio, dialkylsulfonium, sulfate, or phosphate;
R2 is OH, NH2, NR31, SH; or R31 is C1-C6 alkyl and hydrogen;
Rl and R2 may be taken together to form an epoxide ring, an aziridine ring, an episulfide ring, a sulfate ring, a cyclopropyl ring, or monoalkylphosphate ring; or R1 and R2 may be taken together to form a second bond between Cl8 and C19;
R3 is a lower alkyl group;
R4 is H;
R5 is H;
R4 and R5 may be taken together to form a second bond between Cl3 and C19;
R6 is a substituent selected from the group consisting of B-ring heteroaromatic, substituted heteroaromatic, B-ring (C1-CA 02263420 1999-02-ll - W O 98/08506 PCTrUS97/15245 C6) alkyl, (C3-C8)cycloalkyl, substituted C~-C8 cycloalkyl, substituted (Cl-c6) alkyl, a group of the formula III':
,R

\Rl 7 III' and a group of the formula III'':
Rl\

~RI 5 \ 17 R III'';
R7 is selected from the group consisting of H and a lower alkyl group;
R8 is H or a lower alkyl group;
R7 and R8 can optionally form a cyclopropyl ring;
R9 is selected from the group consisting of H, a lower alkyl group, unsaturated lower alkyl, and lower alkyl-C3-C5 cycloalkyl;
Rl~ is H or a lower alkyl group;

R50 is hydrogen or Rll is selected from the group consisting of H, OH, simple alkyl, phenyl, substituted phenyl, benzyl, and substituted benzyl;
Rl4 is H or a lower alkyl group;
R'5, R16, and Rl7 are each independently selected from the group consisting of hydrogen, (Cl-C6)alkyl, OR'~, halo, NRl8R19, NO2, OPO3H2, OR19phenyl, SCH2phenyl, CONH2, CO2H, PO3H2, and So2R23, and ZZ;
Rl8 is selected from the group consisting of hydrogen, aryl, and Cl-C6 alkyl;

- W O 98/08506 PCTrUS97/15245 R~ is selected from the group consisting of hydrogen and ~ (C,-C6)alkyl;
R'9 is C~-C6 alkyl;
Rl9 is selected from the group consisting of hydrogen and (Cl-C6)alkyl;
R23 is selected from the group consisting of hydrogen and (C]-C3) alkyl;
R29 is (Cl-C5)alkyl;
R30 is hydrogen or Cl-C6 alkyli R is hydrogen or a group of the formula n is 0, 1, or 2;
p is 0, 1, or 2;
m is 0, 1, or 2;
X is selected from the group consisting of O, NH and alkylamino;
Y is selected from the group consisting of O, NH, and alkylaminoi Z is selected from the group consisting of -(CH2)n~/ -(CH2)p-O-(CH2) m~ and (C3-C5) cycloalkyl;
ZZ is selected from the group consisting of an aromatic group and a substituted aromatic group; or a pharmaceutically acceptable salt or solvate thereof;
provided that when R6 is a group of Formula III' and n is 1, then at least one of the group consisting of Rl5, R16 and Rl7 must be a non-hydrogen group and if only one of Rl5, Rl6 and Rl7 is OH or oR29 and one of the group consisting of Rl5, Rl6 and Rl7 is halo then the remaining member of the group conslsting of R15 Rl6 and Rl7 must not be hydrogen or halo;
or when R6 is a group of Formula III' and n is 1 then Rl4 is lower alkyl;
further provided that the compound is not a cryptophycin selected from the group consisting of cryptophycins:

. . ~ ~

CA 02263420 1999-02-ll ~,,~ ~0 O ~ O HN ~ ~ Br O ~ N ~ O ~ OCH3 H

B-2, O ~ O HN ~ ~ Cl O ~ N o ~ OCH2CH3 B-7, ~~
O ~ O HN ~ ~ Cl ~ o ~ N ~ O ~ OCH3 C-l, CA 02263420 1999-02-ll - W O 98/08506 PCTrUS97/15245 ~ ~0 ~OJ~N O~O.H3 O ~ N O ~ O~H3 C-3, ~,'~"~

O ~ N O ~ OCH3 .

CA 02263420 1999-02-ll ~,"1 ~.~

o ~ ~ X ~ ~ O~H3 O N ~ O ~ OCH3 O ~ N ~ O ~ OCH3 - W O 98/08506 rcTrusg7/ls24s ~J~ O

~[ O~NXO~ocH3 F ~ O ~ N ~ ~ ~ OCH3 ,~,~'~

F ~ o o HN X ~ ~ ClH3 - W O 98/08506 PCTtUS97tlS245 ~ O

O ~ N ~ O ~ OCH3 e~O~H~

~ O ~ N ~ O ~ OCH3 ~ 0 ~N)~O~OCH3 3'~o~

O ~ N O ~ OCH3 The present invention provides pharmaceutical formulations, a method for disrupting a microtubulin system using an effective amount of a compound of Formula I or I', a method for inhibiting the proliferation of mammalian cells comprising administering an effective amount of a compound of Formula I or I', and a method for treating neoplasia in a mammal comprising administering an effective amount of a compound of Formula I or I'.

As used herein, the term "simple alkyl" shall refer to Cl-C. alkyl wherein the alkyl may be saturated, unsaturated, branched, or straight chain. Examples include, but are in no way limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, propenyl, sec-butyl, n-pentyl, isobutyl, , -- . ... . .

- W O 98/08506 PCT~US97/15245 tert-butyl, sec-butyl, methylated butyl groups, pentyl, tert ~ pentyl, sec-pentyl, methylated pentyl groups and the like.
As used herein, the term "B-ring Cl-C6 alkyl"
refers to saturated, unsaturated, branched and straight chain alkyl wherein the B-ring C~-C6alkyl group may include up to three (3) non-carbon substituents. Such non-carbon substituents are most preferably selected from the group consisting of OH, SCH2phenyl, NH2, CO, CONH2, CO2H, PO3H2, SO2R21 wherein R21 is selected from hydrogen and C,-C~ alkyl;
As used herein, the term "substituted phenyl"
shall refer to a phenyl group with from one to three non-hydrocarbon substituents which may be independently selected from the group consisting of simply alkyl, Cl, Br, F, and I.
As used herein, the term "substituted benzyl"
shall refer to a benzyl group with from one to three non-hydrocarbon substituents which may be independently selected from the group consisting of simply alkyl, Cl, Br, F, and I
wherein such substituents may be attached at any available carbon atom.
As used herein "B-ring heteroaromatic group"
refers to aromatic rings which contain one or more non-carbon substituent selected from the group consisting of oxygen, nitrogen, and sulfur. Especially preferred B-ring heterocyclic groups are selected from, but not limited to, the group consisting of:

- W O 98/08506 PCTrUS97/15245 ~? ~ ~

OR~~

~ and ~ O>

wherein R20 is selected from hydrogen and C1C6 alkyl It is especially preferred that "B-ring heteroaromatic group" refers to a substituent selected from the group consisting of:

OR , ~ , ~ N

OR

S S and N

As used herein, "cycloalkyl" refers to a saturated C,-C8 cycloalkyl group wherein such group may include from zero to three substituents selected from the group - W O 98/08506 PCTrUS97115245 consisting of Cl-C3 alkyl, halo, and OR22 wherein R22 is selected from hydrogen and C~-C~ alkyl. Such substituents may be attached at any available carbon atom. It is especially preferred that cycloalkyl refers to substituted or unsubstituted cyclohexyl.
As used herein, "Lower alkoxyl group" means any alkyl group of one to five carbon atoms bonded to an oxygen atom. As used herein, "lower alkyl group" means an alkyl group of one to five carbons and includes linear and non-linear hydrocarbon chains, including for example, but notlimited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, sec-butyl, methylated butyl groups, pentyl, tert pentyl, sec-pentyl, and methylated pentyl groups. As used herein, allylically substituted alkene"
means any alkene having from one to seven carbon atoms which contain an alkyl substitution on it. As used herein, the term "unsaturated lower alkyl" means a lower alkyl group as defined supra wherein from one to two double bonds are present in the unsaturated lower alkyl substituent. A
preferred unsaturated lower alkyl is -CH2-CH=CH2. The term "lower alkyl-C3-C5 cycloalkyl" refers to C-C alkyl substituted with a C3-C5cycloalkyl group. A preferred lower alkyl-C3-C5 cycloalkyl group is -CH2-cyclopropyl; wherein the group is attached to the cryptophycin core structure at R9 via the CH2.
As used herein "epoxide ring" means a three-membered ring whose backbone consists of two carbons and an oxygen atom. As used herein, "aziridine ring" means a three-membered ring whose backbone consists of two carbon atoms and a nitrogen atom. As used herein, "sulfide ring"
means a three-membered ring whose backbone consists of two carbon atoms and a sulfur atom. As used herein, "episulfide ring" means a three-membered ring whose backbone consists of two carbon atoms and a sulfur atom. As used herein, - W098/08506 PCT~S97/15245 "sulfate group" means a five-membered ring consisting of a ~ carbon-carbon-oxygen-sulfur-oxygen backbone with two additional oxygen atoms connected to the sulfur atom. As used herein, "cyclopropyl ring" means a three-member ring whose backbone consists of three carbon atom. As used herein, "monoalkylphosphate ring" means a five-membered ring consisting of a carbon-carbon-oxygen-phosphorous-oxygen backbone with two additional oxygen atoms, one of which bears a lower alkyl group, connected to the phosphorous atom.
As used herein, "simple unsubstituted aromatic group" refers to common aromatic rings having 4n+2 electrons in a monocyclic conjugated system, for example, but not limited to: furyl, pyrrolyl, thienyl, pyridyl and the like, or a bicyclic conjugated system, for example, but not limited to: indolyl or naphthyl.
As used herein, "simple substituted aromatic group" refers to a phenyl group substituted with a single group selected from the group consisting of halogen and lower alkyl group.
As used herein, "heteroaromatic group" refers to aromatic rings which contain one or more non-carbon substituent selected from the group consisting of oxygen, nitrogen, and sulfur.
As used herein, "halogen" or "halo" refers to those members of the group on the periodic table historically known as halogens. Methods of halogenation include, but are not limited to, the addition of hydrogen halides, substitution at high temperature, photohalogenation, etc., and such methods are known to the skilled artisan.
As used herein, the term "mammal" shall refers to the Mammalia class of higher vertebrates. The term "mammal"
includes, hut is not limited to, a human. The term "treating" as used herein includes phophylaxis of the named ~condition or amelioration or elimination of the condition once it has been established. The cryptophycin compounds claimed herein can be useful for veterinary health purposes as well as for the treatment of a human patient.
Some preferred characteristics of this invention are set forth in the following tabular form wherein the features may be independently selected to provide preferred embodiments of this invention. The invention is in no way limited to the features described below:

A) R~ is ethyl, propyl, isopropyl, butyl, isobutyl or isopentyl;
B) R7 is ethyl, propyl, isopropyl, butyl isobutyl, pentyl, or isopentyli C) R7 is H, R~ is methyl, R3 is methyl, and X and Y are not both O;
D) R3 is ethyl, propyl, isopropyl, butyl, isobutyl, pentyl or isopentyli 20E) R9 is methyl, ethyl, propyl, butyl, isobutyl, pentyl, or isopentyl;
F) Rl~ is methyl, ethyl, propyl, butyl, isobutyl, pentyl, or isopentyli G) a crytophycin compound wherein at least one of the groups selected from the group consisting of C-3, C-6, C-7, C-10, C-16, C-17, and C-18 has R stereochemistry (numbering as set forth in Formula I supra. );
H) a cryptophycin compound wherein at least one of the groups selected from the group consisting of C-3, C-6, C-7, C-10, C-16, C-17, and C-18 has S stereochemistry (numbering as set forth in Formula I supra. );
I) Ar is phenyl with a substituent selected from the group consisting of hydrogen, halogen, and simple alkyl;
J) a compound wherein Y is O' CA 02263420 1999-02-ll - WO 98/08506 PCTrUS97/15245 K) a compound wherein Y is O, R , R~, R~ and R'~ are each ~ hydrogen; and R' and R2 form an epoxide;
L) R7, R8 are each hydrogen M) R~ and R3 are each selected from hydrogen and CH3;
5N) Y is Oi O) R is selected from the group consisting of methyl, ethyl, n-propyl, and phenyl;
P) R' and RZ form an epoxide ring;
Q) both X and Y are O;
lOR) R4 and R5 form a double bond;
S) n is 0; R6 is substituted benzyl wherein one substituent is a halogen and one is an oR'2 group wherein Rl2 is lower alkyl;
T) a compound of Formula I is used for disruption of a microtubulin system;
U) a compound of Formula I is used as an anti-neoplastic agent;
V) a compound of Formula I is used for the treatment of cancer in a mammal;
W) a compound of Formula I is used as an antifungal agent;
20X) R6 is Formula III' and is para hydroxy substituted;
Y) R6 is selected from the group consisting of .....

I ' ~ OH
~,~ , o~3 , ~, NH

N

NH2 ~ and Nl+

Z) Z is -(CH2) n~ wherein n is 0;
AA) Z is -(CH2) n- wherein n is 2;
BB) Z is -(CH2)rl- wherein n is 1;
CC) Rfi is Formula III'i DD) R6 is Formula III'';
EE) Rfi is C3-C6 cycloalkyl;
FF) Rfi is selected from the group consisting of B-ring heteroaromatic, substituted heteroaromatic, B-ring CA 02263420 1999-02-ll alkyl, cycloalkyl, substituted cycloalkyl, Formula III' and ~ Formula III'';
GG) at least one of Rl5, Rl6, and R~7 is selected from the group consisting of SCH2phenyl, NH2, CO, CONH2, CO2H, Po3H2/ and So2R2l; wherein R2l is selected from hydrogen and Cl-C3 alkyl;
HH ) Ar is phenyl;
II) Ar is phenyl substituted with one or two from the group consisting of OH, OCH3, halo, and methyl; and Ar is naphthyl;
KK) R6 has a Z wherein the first carbon of the Z

group is ' "~~~ with respect to the point o~ attachment to the cryptophycin molecule;
LL) R6 is a heteroaromatic ring;
MM) R7 is selected from the group consisting of N (CH3) 2~ CH2N (CH3) 2;
NN) R7 is CH2OCH3i OO) R7 is cyclopropyl;
PP) R9 is CH2cyclopropyl;
QQ) R9 is CH2cH=cH2;
RR) R6 is selected from the group consisting of .. ,. j - W 098/08506 PCTrUS97/15245 /~¢~NH2 l ~NH2 NH, ~ ~ OH

NHCH3 r NHCH3 ~

~ NICH ) ~ N;CH3)2 To further illustrate, but to no way limit, the compounds contemplated herein, the following table of especially preferred compounds is provided: A compound wherein R3 is CH3; R4 and R5 together form a second bond; Rl4 is hydrogen; R30 is hydrogen; R7 and R3 are each methyl; R'~
is hydrogen; R'~ is hydrogen; R9 is -CH2CH(CH3) 2; X and Y are each O; Ar is phenyl; and Rl R2 R6 "''13 together form a double bond CA 02263420 l999-02-ll - W O 98/08506 PCTrUS97/15245 - Rl R2 R6 ~ ~P~4 H2 together form an epoxide ~;

together form an epoxlde ~;

together form a double bond "''13 Cl OH

~""' ~;

Cl OH

~""~;

together form a double bond ""'~;

together form an epoxide . .... . ~ . .. .. . .. . . . .. . . . .

PCT~US97115245 W O~lOU'~6 Rl R2 R6 ~ ~ Cl " ~ OH ;
Cl OH

",.,oJ3;

together form a double bond ",.,oJ3 Cl OH

~ i together form a double bond ""'''O
together form a double bond Cl OH

Additional preferred compounds are those named above except ~CI

that Ar is 3 instead of phenyl.
Further preferred compounds are those named above except that - W O 98/08506 PCT~US97tlS245 Ar is OCH~

The present lnvention provides a method of alleviating a pathological condition caused by hyperproliferating mammalian cells comprising administering to a subject an effective amount of a pharmaceutical or veterinary composition disclosed herein to inhibit proliferation of the cells. In a preferred embodiment of this invention, the method further comprises administering to the subject at least one additional therapy directed to alleviating the pathological condition. In a preferred embodiment of the present invention, the pathological condition is characterized by the formation of neoplasms.
In a further preferred embodiment of the present invention, the neoplasms are selected from the group consisting of mammary, small-cell lung, non-small-cell lung, colorectal, leukemia, melanoma, pancreatic adenocarcinoma, central nervous system (CNS), ovarian, prostate, sarcoma of soft tissue or bone, head and neck, gastric which includes pancreatic and esophageal, stomach, myeloma, bladder, renal, neuroendocrine which includes thyroid and non-Hodgkin's disease and Hodgkin's disease neoplasms.
As used herein "neoplastic" refers to a neoplasm, which is an abnormal growth, such growth occurring because of a proliferation of cells not subject to the usual limitations of growth. As used herein, "anti-neoplastic agent" is any compound, composition, admixture, co-mixture, or blend which inhibits, eliminates, retards, or reverses the neoplastic phenotype of a cell.
Anti-mitotic agents may be classified into three groups on the basis of their molecular mechanism of action.
The first group consists of agents, including colchicine and colcemid, which inhibit the formation of microtubules by sequestering tubulin. The second group consists of agents, .

- W098/08506 PCT~S97/lS245 including vinblastine and vincristine, which induce the formation of paracrystalline aggregates of tubulin.
Vinblastine and vincristine are well known anticancer drugs:
their action of disrupting mitotic spindle microtubules preferentially inhibits hyperproliferative cells. The third group consists of agents, including taxol, which promote the polymerization of tubulin and thus stabilizes microtubules.
The exhibition of drug resistance and multiple-drug resistance phenotype by many tumor cells and the clinically proven mode of action of anti-microtubule agents against neoplastic cells necessitates the development of anti-microtubule agents cytotoxic to non-drug resistant neoplastic cells as well as cytotoxic to neoplastic cells with a drug resistant phenotype.
Chemotherapy, surgery, radiation therpy, therapy with biological response modifiers, and immunotherapy are currently used in the treatment of cancer. Each mode of therapy has specific indications which are known to those of ordinary skill in the art, and one or all may be employed in an attempt to achieve total destruction of neoplastic cells.
Moreover, combination chemotherapy, chemotherapy utilizing compounds of Formula I in combination with other neoplastic agents, is also provided by the subject invention as combination therapy is generally more effective than the use of a single anti-neoplastic agent. Thus, a further aspect of the present invention provides compositions containing a therapeutically effective amount of at least one compound of Formula I, including the non-toxic addition salts thereof, which serve to provide the above recited benefits. Such compositions can also be provided together with physiologically tolerable liquid, gel, or solid carriers, diluents, adjuvants and excipients. Such carriers, adjuvants, and excipients may be found in the U.S.
Pharmacopeia, Vol. XXII and National Formulary vol XVII, U.S. Pharmacopeia Convention, Inc. Rockville, MD (1989).
Additional modes of treatment are provided in AHFS Drug - W O 98/08506 PCT~US97115245 Information, 1993 e. by the American Hospital Formulary Service, pp. 522-660. Each of these references are well known and readily available to the skilled artisan.
The present invention further provides a pharmaceutical composition used to treat neoplastic disease containing at least one compound of Formula I and at least one additional anti-neoplastic agent. Anti-neoplastic agents which may be utilized in combination with Formula I
compounds include those provided in the Merck Index 11, pp 16-17, Merck & Co., Inc. (1989). The Merck Index is widely recognized and readily available to the skilled artisan.
In a further embodiment of this invention, antineoplastic agents may be antimetabolites which may include but are in no way limited to those selected from the group consisting of methotrexate, 5-fluorouracil, 6-mercaptopurine, cytosine, arabinoside, hydroxyurea, and 2-chlorodeoxyadenosine. In another embodiment of the present invention, the anti-neoplastic agents contemplated are alkylating agents which may include but are in no way limited to those selected from the group consisting of cyclophosphamide, mephalan, busulfan, paraplatin, chlorambucil, and nitrogen mustard. In a further embodiment, the anti-neoplastic agents are plant alkaloids which may include but are in no way limited to those selected from the group consisting of vincristine, vinblastine, taxol, and etoposide. In a further embodiment, the anti-neoplastic agents contemplated are antibiotics which may include, but are in no way limited to those selected from the group consisting of doxorubicin, daunorubicin, mitomycin C, and bleomycin. In a further embodiment, the anti-neoplastic agents contemplated are hormones which may include, but are in no way limited to those selected from the group consisting of calusterone, diomostavolone, propionate, epitiostanol, mepitiostane, testolactone, tamoxifen, polyestradiol phosphate, megesterol acetate, flutamide, nilutamide, and trilotane.

W O 98/08506 PCTrUS97/15245 In a further embodiment, the anti-neoplastic agents contemplated include enzymes which may include, but are in no way limited to those selected from the group consisting of L-Asparginase and aminoacridine derivatives such as, but not limited to, amsacrine. Additional anti-neoplastic agents include those provided by Skeel, Roland T., "Antineop~astic Drugs and Biologic Response Modifier:
Classification, Use and Toxicity of Clinically Useful Agents" Handbook of Cancer Chemotherapy (3rd ed.), Little Brown & Co. (1991).
These compounds and compositions can be administered to m~mm~ls for veterinary use. For example, domestic animals can be treated in much the same way as a human clinical patient. In general, the dosage required for therapeutic effect will vary according to the type of use, mode of administration, as well as the particularized requirements of the individual hosts. Typically, dosages will range from about 0.001 to 1000 mg/kg, and more usually 0.01 to 10 mg/kg of the host body weight. Alternatively, dosages within these ranges can be administered by constant infusion over an extended period of time, usually exceeding 24 hours, until the desired therapeutic benefits are obtained. Indeed, drug dosage, as well as route of administration, must be selected on the basis of relative effectiveness, relative toxicity, growth characteristics of tumor and effect of Formula I compound on cell cycle, drug pharmacokinetics, age, sex, physical condition of the patient and prior treatment, which can be determined by the skilled artisan.
The compound of Formula I, with or without additional anti-neoplastic agents, may be formulated into therapeutic compositions as natural or salt forms.
Pharmaceutically acceptable non-toxic salts include base addition salts which may be derived from inorganic bases such as for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as W O 98108506 PCTrUS97/15245 isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine, and the like. Such salts may also be formed as acid addition salts with any free cationic groups and will generally be formed with inorganic acids such as for example, hydrochloric or phosphoric acids or organic acids such as acetic, oxalic, tartaric, mandelic, and the like. Additional excipients which further the invention are provided to the skilled artisan for example in the U.S.
Pharmacopeia .
The suitability of particular carriers for inclusion in a given therapeutic composition depends on the preferred route of administration. For example, anti-neoplastic compositions may be formulated for oral administration. Such compositions are typically prepared as liquid solution or suspensions or in solid forms. Oral formulation usually include such additives as binders, fillers, carriers, preservatives, stabilizing agents, emulsifiers, buffers, mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, magnesium carbonate, and the like. These compositions may take the form of solutions, suspensions, tablets, pills, capsules, sustained relsease formulations, or powders, and typically contain 1%
to g5% of active ingedient. More preferably, the composition contains from about 2% to about 70% active ingredient.
Compositions of the present invention may be prepared as injectables, either as liquid solutions, suspensions, or emulsions; solid forms suitable for solution in or suspension in liquid prior to injection. Such injectables may be administered subcutaneously, intravenously, intraperitoneally, intramuscularly, intrathecally, or intrapleurally. The active ingredient or ingredients are often mixed with diluents, carriers, or excipients which are physiologically tolerable and compatible with the active ingredient~s). Suitable diluents and excipients are for example, water, saline, dextrose, , - W O 98t08S06 PCTrUS97/15245 glycerol, or the like and combinations thereof. In addition, lf desired, the compositions may contain minor amounts of auxilary substances such as wetting or emulsifying agents, stabilizing or pH buffering agents.
The invention further provides methods for using Formula I compounds to inhibit the proliferation of mammalian cells by contacting these cells with a Formula I
compound in an amount sufficient to inhibit the proliferation of the mammalian cell. A preferred embodiment is a method to inhibit the proliferation of hyperproliferative mammalian cells. For purposes of this invention "hyperproliferative mammalian cells" are mammalian cells which are not subject to the characteristic limitations of growth (programmed cell death for example).
A further preferred embodiment is when the mammalian cell is human. The invention further provides contacting the mammalian cell with at least one Formula I compound and at least one anti-neoplastic agent. The types of anti-neoplastic agents contemplated are discussed supra.
The invention further provides methods for using a compound of Formula I ~o inhibit the proliferation of hyperproliferative cells with drug-resistant phenotypes, including those with multiple drug-resistant phenotypes, by contacting said cell with a compound of Formula I in an amount sufficient to inhibit the proliferation of a hyperproliferative mammalian cell. A preferred embodiment is when the m~mm~lian cell is human. The invention further provides contacting a Formula I compound and at least one additional anti-neoplastic agent, discussed supra.
The invention provides a method for alleviating pathological conditions caused by hyperproliferating mammalian cells for example, neoplasia, by administering to a subject an effective amount of a pharmaceutical composition containing Formula I compound to inhibit the proliferation of the hyperproliferating cells. As used herein "pathological condition" refers to any pathology - W O 98/08506 PCT~US97115245 arising from the proliferation of mammalian cells that are not subject to the normal limitations of growth. Such proliferation of cells may be due to neoplasms as discussed supra.
In a further preferred embodiment the neoplastic cells are human. The present invention provides methods of alleviating such pathological conditions utilizing a compound of Formula I in combination with other therapies, as well as other anti-neoplastic agents.
The effectiveness of the claimed compounds can be assessed using standard methods known to the skilled artisan.
Examples of such methods are as follows:
Compounds of this invention have been found to be useful against pathogenic fungi. For example, the usefulness for treating Cryptococcus neoformans can be illustrated with test results against Cryptococcus neoformans employing yeast nitrogen base detrose agar medium. In carrying out the assay, a compound of this invention is solubilized in dimethyl sulfoxide supplemented with Tween 20. Twofold dilutions are made with sterile distilled water/10 percent DMS0 to obtain final drug concentrations in the agar dilution assay plates ranging from 0.008 ug/ml to 16.0 ug/ml against an expanded panel of 89 Cryptococcus neoformans strains. The minimum inhibitory concentration against the panel of 84 Cryptococcus neoformans isolates is determined to illustrate the desired antifungal activity.
The compounds are screened for minimum inhibitory concentrations against KB, a human nasopharyngeal carcinoma cell line, LoVo, a human colorectal adenocarcinoma cell line using The Corbett assay, see Corbett, T.H. et al. Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery and Development, pp 35-87, Kluwer Academic Publishers: Norwell, 1992. see also, Valeriote, et al. Discovery and Development of Anticancer Agents; Kluwer Academic Publishers, Norwell, 1993 is used for the evaluation of compounds.
The most active compounds are further evaluated for cytotoxicity against four different cell types, for example a murine leukemia, a murine solid tumor, a human solid tumor, and a low malignancy fibroblast using the Corbett assay.
The compounds are further evaluated against a broad spectrum of murine and human tumors implanted in mice, including drug resistant tumors.
Tumor burden (T/C) ~mean tumor burden in treated animals versus mean tumor burden in untreated animals) are used as a further assessment. T/C values that are less than 42~ are considered to be active by National Cancer Institute Standards; T/C values less than 10~ are considered to have excellent activity and potential clinical activity by National Cancer Institute standards.

Materials Vinblastine, cytochalasin B, tetramethylrhodamine isothiocyanate (TRITC)-phalloidin, sulforhodamine B tSRB) and antibodies against ~-tubulin and vimentin are commercially available from recognized commercial vendors.
Basal Medium Eagle containing Earle's salts (BME~ and Fetal Bovine Serum (FBS) are also commercially available.

Cell Lines The Jurkat T cell leukemia line and A-10 rat aortic smooth muscle cells are obtained from the American Type Culture Collection and are cultured in BME containing 10~
FBS and 50~ug/mL gentamycin sulfate. Human ovarian carcinoma cells (SKOV3) and a sub-line which has been selected fro resistance to vinblastine (SKVLB1~ were a generous gift from Dr. Victor Ling of the Ontario Cancer Institute. Both cell lines are maintained in BME containing 10% FBS and 50ug/mL
gentamycin sulfate. Vinblastine is added to a final W O 98/08506 PCTrUS97/lS245 concentration of lug/mL to SKVLB1 cells 24 hours after passage to maintain selection pressure for P-glycoprotein-overexpressing cells.

Cell Proliferation and Cycle Arrest Assays Cell proliferation assays are performed as described by Skehan et al. For Jurkat cells, cultures are treated with the indicated drugs as described in Skehan and total cell numbers are determined by counting the cells in a hemacytometer. The percentage of cells in mitosis are determined by staining with 0.4% Giemsa in PBS followed by rapid washes with PBS. At least 1000 cells per treatment are scored for the presence of mitotic figures and the mitotic index is calculated as the ration of the cells with mitotic figures to the total number of cells counted.

Immunofluorescence Assays A-10 cells are grown to near-confluency on glass coverslips in BME/10% FBS. Compounds in PBS are added to the indicated final concentrations and cells are incubated for an additional 24 hours. For the staining of microtubules and intermediate filaments, the cells are fixed with cold methanol and incubated with PBS containing 10%
calf serum to block nonspecific binding sites. Cells are then incubated at 37_C for 60 min. with either monoclonal anti-~-tubulin or with monoclonal anti-vimentin at dilutions recommended by the manufacturer. Bound primary antibodies are subsequently visualized by a 45-minute incubation with fluorescein-conjugated rabbit antimouse IgG. The coverslips are mounted on microscope slides and the fluorescence patterns are examined and photographed using a Zeiss Photomicroscope Ill equipped with epifluorescence optics for fluorescein. For staining of microfilaments, cells are fixed with 3% paraformaldehyde, permeabilized with 0.2%
Triton X-100 and chemically reduced with sodium borohydride (lmg/ML). PBS containing lOOnM TRITC-phalloidin is then ., ~ ~ " . .... . . .

CA 02263420 1999-02-ll - W O 98/08506 PCT~US97/15245 added and the mixture is allowed to incubate for 45 min. at 37_C. The cells are washed rapidly with PBS before the coverslips are mounted and immediately photographed as described above.

Effects of cryptophycins and vinblastine on Jurkat cell proliferation and cell cycle Dose-response curves for the effects of cryptophycin compounds and vinblastine on cell proliferation and the percentage of cells in mitosis are determined.

Effects of cytochalasin B, vinblastine and cryptophycins on the cytoskeleton Aortic smooth muscle (A-10) cells are grown on glass coverslips and treated with PBS, 2~M cytochalasin B, lOOnM
vinblastine or lOnM cryptophycin compounds . After 24 hours, microtubules and vimentin intermediate filaments are visualized by indirect immunofluorescence and microfilaments are stained using TRITC - phalloidin. The morphological effects of each drug is examined. Untreated cells displayed extensive microtubule networks complete with perinuclear microtubule organizing centers. Vimentin intermediate filaments were also evenly distributed throughout the cytoplasm, while bundles of microfilaments were concentrated along the major axis of the cell. Cytochalasin B caused complete depolymerization of microfilaments along with the accumulation of paracrystalline remnants. This compound did not affect the distribution of either microtubules or intermediate filaments. The cryptophycin treated microtubules and vimentin intermediates are observed for depletion of microtubules, and collapse of rimentin intermediate filaments.

' W O 98/08506 PCT~US97/15245 Effects of cryptophycins and vinblastine on taxol-stabilized microtubules A-10 cells are treated for 3 hours with 0 or 10~M taxol before the addition of PBS, 100nM vinblastine or 10nM
cryptophycin compound. After 24 hours, microtubule organization is examined by immunofluorescence as described above. Compared with those in control cells, microtubules in taxol-treated cells were extensively bundled, especially in the cell polar regions. As before, vinblastine caused complete depolymerization of microtubules non-pretreated cells. However, pretreatment with taxol prevented microtubule depolymerization in response to vinblastine.
Similarly, microtubules pretreated with taxol are observed with cryptophycin treatment.
Reversibility of microtubule depolymerization by vinblastine and cryptophycin A-10 cells are treated with either 100nM vinblastine or 10nM cryptophycins for 24 hr., resulting in complete microtubule depolymerization. The cells are then washed and incubated in drug-free medium for periods of 1 hour or 24 hours. Microtubules repolymerized rapidly after the removal of vinblastine, showing significant levels of microtubules after 1 hour and complete morphological recovery by 24 hour.
Cells are visualized for microtubule state after treatment with a cryptophycin compound of this invention at either 1 hour or 24 hours after removal of the cryptophycin compounds.

Effects of combinations of vinblastine and cryptophycins on cell proliferation SKOV3 cells are treated with combinations of cryptophycins and vinblastine for 48 hours. The percentages of surviving cells are then determined and the ICsos for each combination is calculated.

CA 02263420 1999-02-ll - W O 98~'t~CC' PCT~US97/15245 Toxicity of cryptophycins, vinblastine and taxol toward SKOV3 and SKVLB1 cells SKVLB1 cells are resistant to natural product anticancer drugs because of their over expression of P-glycoprotein. The abilities of taxol, vinblastine andcryptophycin compounds to inhibit the growth of SKOV3 and SKVLB1 cells are observed. Taxol caused dose-dependent inhibition of the proliferation of both cell lines with ICsos for SKOV3 and SKVLB1 cells of 1 and 8000nM, respectively. Vinblastine also inhibited the growth of both cell lines, with ICsos of 0.35 and 4200nM for SKOV3 and SKVLB1 cells, respectively. Cryptophycins compounds of this invention demonstrate activity with an Icsos of from about 1 to about 1000pm for SKOV3 and SKVLB1 cells.
Thus it can be demonstrated that the present invention provides novel cryptophycin compounds which are potent inhibitors of cell proliferation, acting by disruption of the microtubule network and inhibition of mitosis. These studies can illustrate that cryptophycin compounds disrupt microtubule organization and thus normal cellular functions, including those of mitosis.
Classic anti-microtubule agents, such as colchicine and vinca alkaloids, arrest cell division at mitosis. It seems appropriate to compare the effect of one of these agents on cell proliferation with the cryptophycin compounds. For this purpose, the vinca alkaloid vinblastine was selected as representative of the classic anti-microtubule agents.
Accordingly, the effect of cryptophycin compounds and vinblastine on the proliferation and cell cycle progression of the Jurkat T-cell leukemia cell line is compared.
Since antimitotic effects are commonly mediated by disruption of microtubules in the mitotic spindles, the effects of cryptophycin compounds on cytoskeletal structures are characterized by fluorescence microscopy.
Immunofluorescence staining of cells treated with either a cryptophycin compound or vinblastine demonstrate that both - W O 98/08S06 PCTrUS97115245 compounds cause the complete loss of microtubules. Similar studies with SKOV3 cells can show that the anti-microtubule Effects of cryptophycin compounds are not unique to the smooth muscle cell line.

GC3 Human Colon Carcinoma Screen Selected wells of a 96 well plate were seeded with GC3 human colon carcinoma cells (lx10 cells in a 100111 assay medium/well) twenty-four hours prior to test compound addition. Cell free assay medium was added to other select wells of the 96 well plate. The assay medium (RPMI-1640 was the medium used; however, any medium that will allow the cells to survive would be acceptable) was supplemented with 10~ dialyzed fetal bovine serum and 25 MM HEPES buffer.
The test compound was stored in an amber bottle prior to testing. Fresh dimethylsulfoxide stock solution (200ug/ml) was prepared immediately prior to preparation of test sample dilutions in phosphate-buffered saline (PBS). A
dilution of 1:20 dimethylsulfoxide solution in PBS was prepared such that the final concentration was 10 ug/ml.
Serial 1:3 dilutions using PBS (.5ml previous sample of lml PBS) were prepared. Falcon 2054 tubes were used for the assay.
A 10,ul sample of each dilution of test compound was added in triplicate to wells of GC3 plates. The plates were incubated for 72 hours at about 37~C. A 10ul sample of stock 3-[9,5-dimethyl-2-yl]-2,5-diphenyltetrazolium bromide salt ("MTT" 5mg/ml in PBS) was added to each well. The plates were incubated for about an hour at 37~C. The plates were centrifuged, media was decanted from the wells and 100ul acid-isopropanol (0.04 N HCl in isopropanol) was added to each well. The plate was read within one hour using a test wavelength of 570nm (SpectraMax reader).

CA 02263420 1999-02-ll W O 98/08506 PCT~US97/15245 Evaluation of compounds of Formula I suggest that the compounds can be useful in the treatment methods claimed herein. Further, the compounds will be useful for disrupting the microtubule system.
Compounds of Formula I can be prepared using a compound of the Formula II

Ar ~~X oR2 4 1~l R Y ~ NHRl3 R R R
II
wherein 1 2 3 R4 R5R6 R7 R8, R9, Rl~ have the meanings set for supra in Formula I.
Rl3 is selected from the group consisting of t-butylcarbamate (BOC);
R24 is selected from the group consisting of 1~l '~P
~ (N-hydroxysuccinimide, herein "NHS"), N-hydroxysulfosuccinimide and salts thereof, 2-nitrophenyl, 4-nitrophenyl, and 2,9-dichlorophenyl;
X is 0, NH or alkylamino;
Y is O, NH, or alkylamino.

- W O 98/08506 PCTrUS97/15245 Compounds of Formul a I I I

Ar~
O~X HN_ IR6 R Y~NHR1 3 2 R R R

III

wherein the R groups and various substituents are as defined hereinbefore and throughout the specification; can be prepared by contacting a compound of the Formula IV

Ar ~
O~X oR25 ~NHRl3 R R R
IV

R25 is an active ester substituent;
with an acid of the formula N\HI~R6 R27 is selected from the group consisting of H, Cl-CI2 alkyl, and aryl;

.. . ... .

and a silylating agent. Bis N, O-trimethylsilyl acetamide ~ (BSA) is an especially preferred silylating agent.
As used with regard to R25 the phrase "active ester substituent" refers to a substituent which makes the oR24 substituent a good leaving group. Appropriate substituents can be selected with guidance from standard reference guides, for example, "Protective Groups in Organic Chemistry", Plenum Press, (London and New York, 1973);
Greene, T.W. "Protecting Groups in Organic Synthesis", Wiley (New York, 1981). An especially preferred R25 group is N-hydroxy-succinimide. (NHS) The processes described herein are most preferably completed in the presence of a solvent. The artisan can select an appropriate solvent for the above described process. Inert organic solvents are particularly preferred;
however, under certain conditions an aqueous solvent can be appropriate. For example, if R27 is hydrogen and R13 is BOC
an aqueous base as solvent will be effective.
When the desired R6 substituent in the compound of Formula I contains an amine, then the amine substituent of the R6 group must be protected using an amino protecting group. The artisan can readily select an appropriate amino protecting group using guidance from standard works, including for example, "protective Groups in Organic 2~ Chemistry", Plenum Press, (London and New York, 1973);
Greene, T.W. "Protecting Groups in Organic Synthesis", Wiley (New York, 1981).
R27 should be a group that allows for the removal of the -Co2R27 substituent using acidic, neutral, or mild basic conditions. Preferred R27 groups include, but are in no way limited to, hydrogen, C~-C6 alkyl, trichloromethyl, trichloroethyl, and methylthiomethyl. It is especially preferred that R27 is hydrogen.

To provide further guidance for the artisan, the ~ following schemes are provided:
Scheme 1 ~ lN aq LiOH ~ ~
OTBS MeO Acetone ~ OTBS OH

EDC,NSH, w ~H3 H3~
50~ aq ~ O
OH O~ ~ CH3CN ~ J OTBS O~

~oO ~0 Scheme I' Ar ~ Me Ar ~ o oR26 OH

Ar ~ Ar ~

o~ oR26 ~o As used in Scheme I' and throughout the specification, R1 is halogen, SH, amino, monoalkylamino, dialkylamino, trialkylammonium, alkylthio, dialkylsulfonium, sulfate, phosphate or a protected OH or protected SH group;

. , ~ W O 98/08506 PCT~US97/15245 R2 is OH or SH; R26 is an alcohol protecting group introduced during a portion of the synthetic process to protect an alcohol group which might otherwise react in the course of chemical manipulations, and is then removed at a later state of the synthesis. Numerous reactions for the formation and removal of such protecting groups are described in a number of standard works, including, for example, "protective Groups in Organic Chemistry", Plenum Press, tLondon and New York, 1973); Greene, T.W. "Protecting Groups in Organic Synthesis", Wiley ~New York, 1981). The skilled artisan can select an appropriate alcohol protecting group particularly with guidance provided from such works. One particularly useful alcohol protecting group is tert-butyldimethylsilyl (TBS).

CH3 fO2H O
~ ~ o ~ NHBoc OH ONHS

~0 ~,~,~ fO
O ~ ~ HN ~ R (v) ~ O O ONHS
CO~H E ~ O NHBoc ? ~ 6 O ~ O H ~ R

H

R6 has the meaning defined supra.

~ W O 98108506 PCTrUS97/15245 o q~O ~lN,~R

O ~ N ~
'' H

mcpba fO
1~1q~ HN~R

O ~ N ~
H

¦TMSCl/separate Cl CH3 ~
O Cl ICH3 OH - HN R6 ~ O

~N~o ~ o II~R

base base w ~1~
~~ 0,~~
~~~ o HN~ ~ R6 ~ ~ ~ ~ ~--0 ~N "(~~ J~N ~

- W O 98/08506 PCTrUS97/15245 The product of the schemes provided herein can be further derivatized using standard methods to provide further cryptophycin compounds.
The artisan can utilize appropriate starting materials and reagents to prepare desired compounds using the guidance of the previous schemes and following examples.
The ester starting material can be prepared, for example, as follows:

CHO

Step 1 HEW
w TMG
CO2Me Step 2 DIBAL

OH

Step 3 SAE

OH

Step 4 Me3Al Me OH SteP 5 OH Bu2Sn=o ~" TsCl, TEA

~ W O 98/08506 PCTtus97tl5245 Me OTs OH
Step 6 TBS-OTf Et3N
e OTs OTBS
Step 7 NBS/AIBN

Br Me OTs OTBS

Step 8 DBU/ACN

Me OTs OTBS
Step 9 KCN

Me CN
OTBS
Step 1 0 DIBAL;
HEW

Me ~~
OTBS OMe R6 has the meaning defined supra.

... .~ .. . ~

- W O 98/08506 PCTrUS97/15245 The scheme for preparing the ester is further ~ explained by the Preparation Section herein which provides one specific application of the scheme for the convenience of the skilled artisan.
The Scheme for preparing the ester is applicable to the Ar substituents claimed herein. The scheme illustration is not intended to limit the synthesis scheme only to the phenyl ring illustrated. Rather, the artisan can broadly apply this process to provide desired starting materials for the compounds claimed herein.
The necessary reaction time is related to the starting materials and operating temperature. The optimum reaction time for a given process is, as always, a compromise which is determined by considering the competing goals of throughput, which is favored by short reaction times, and maximum yield, which is favored by long reaction times.
To further illustrate the invention the following examples are provided The scope of the invention is in no way to be construed as limited to or by the following examples.

Preparation 1 Step 1. Methyl 5-Phenylpent-2(E)-enoate. A solution of trimethyl phosphonoacetate (376 g, 417 mL, 2.7 mol) in THF
(750 mL) was stirred at 0~C in a 3L 3-neck round bottom flask equipped with a mechanical stirrer and N2 inlet. To the chilled solution, neat tetramethyl guanidine (239 g, 260 mL, 2.07 mol) was added dropwise via an addition funnel.
The chilled clear pale yellow solution was stirred for 25 minutes at 0~C. A solution of hydrocinnamaldehyde (90%, 253 g, 248 mL, 1.9 mol) in THF (125 mL) was added dropwise to the reaction solution slowly. Upon completion of addition, the reaction was stirred for 10 h rising to room CA 02263420 l999-02-ll - W O 98/08506 PCT~US97/15245 temperature. GC indicated at 95:5 ratio of product to starting material. 500 ml of water was added to the reaction vessel and the reaction stirred overnight separating into two layers. The organic layer was isolated and the aqueous layer was extracted with t-BuOMe. The organic layers were combined and dried over MgSO4, then concentrated in vacuo to yield an orange oil. The crude product was distilled at 129~C/0.3mm Hg yielding 360.5g, 91.7~ yield, of a clear slightly yellow oil.
EIMS m/z 190(13; M+), 159(410, 158(39~, 131(90), 130(62), 117(22), 104(12), 95(57), 91(100), 77(21), 65(59); HREIMS
m/z 190.0998 (C12H14O2 D -0.~ mnu); W lmax (e) 210 (8400), 260 (230) nm; IR nmax 3027, 2949, 1723, 1658, 1~59, 1319, 1203, 978, 700 cm~l; lH NMR d (CDCl3) 7.15-7.3 (Ph-H5;bm), 7.00 (3-H;dt, 15.6/6.6), 5.84 (2-H;dt, 15.6/1.2), 3.70 (OMe;s), 2.76 (5-H2;t, 7.2), 2.51 (9-H2; bdt, 6.6/7.2); 13C
NMR d (CDC13) 166.9 (1), 148.3(3), 190.6(Ph-1'), 128.9/128.2 (Ph2'/3'/5'6'), 126.1 (Ph 4'), 121.9 (2). 51.3 (OMe), 34.2/33.8 (4/5).
Step 2. 5-phenyl-pent-2-en-1-ol. To a 12L 4-neck round bottom flask equipped with a thermocouple, mechanical stirrer and N2 inlet, a solution of enoate ester (310.5 g, 1.5 mol) in THF (1.5 L) was charged and chilled to -71~C via a i-PrOH/CO2 bath. To the reaction vessel, was added dropwise DIBAL (2.5 L, 1.5 M in toluene, 3.75 mol) at a rate to maintain the reaction temperature < -50~C. Upon complete addition, the reaction was stirred overnight with the reaction temperature < -50~C. TLC (3:1 Hexanes:EtOAc, SiO
indicated absence of starting material after 16 h. The reaction temperature was allowed to raise to -15 C. The reaction was quenched slowly withlN HCl (150 mL). At this point the reaction setup into a gelatinous solid. A spatula was employed to breakup the the semi-solid and lN HCl ~200 mL) was added making the mixture more fluid. Concentrated HCl (625 mL) was charged to form a two phase system. The CA 02263420 1999-02-ll - W O 98/08506 PCTrUS97/15245 layers were separated and the product extracted with t-BuOMe. The organic layer was dried over MgSO4 and concentrated in vacuo to yield a clear pale yellow oil, 247.8g. The crude product was distilled at 145~C/0.~5mm Hg yielding 209.7g, 86.2~.
EIMS m/z 1~2 (l:M+) 144 (16), 129 (7), 117 (9) 108 (6), 92 (17), 91 (100), 75 (5), 65 (12), HREIMS m/z 162, 1049 (C11H140, D -0.4 mmu); W lmax (e) 206 (9900), 260 (360); IR
nmax 3356, 2924, 1603, 1496, 1454, 970, 746, 700 cm~ H
NMR d 7.15-7.3 (Ph-H5;m), 5.70 (3-H;dt, 15.6/6.0), 5.61 (2-H;dt, 15.6/4.8), 4.02 (1-H2;d 4.8), 2.68 (5-H2; t, 7.2), 2.40 (OH;bs), 2.3~(4-H2; ~t, 6.0/7.2); 13C NMR dl41.6 (Ph 1'), 131.8(3), 129.5 (2), 128.3/128.2 (Ph 2'/3'/5'/6'), 125.7 (Ph 4'), 63.3 (1), 35.4/33.8 (4/5).
Step 3. (2S,3S)-2,3-Epoxy-5-phenyl-1-pentanol. To a lL 3 neck round bottom flask equipped with a mechanical stirrer, thermocouple and nitrogen inlet was added CH2Cl2 (350 mL), dried 4 A molecular sieves (30 g) and L-(+)-diethyl tartrate (7.62 g, 0.037 mol). The resulting mixture was cooled to -20 ~C and treated with Ti(O-i-Pr)4 (9.2 mL, 0.031 mol), followed by the addition of t-butylhydroperoxide (4.0 M in CH2Cl2, 182 mL, 0.78 mol) at a rate to maintain the temperature ~ -20~C. Upon complete addition, the reaction mixture was stirred for another 30 min, and then treated with a solution of the allylic alcohol (50 g, 0.31 mol) in CH2Cl2 (30 mL) at a rate to maintain the temperature 2 -20~C. The reaction was stirred at the same temperature for 5 h, then filtered into a solution of ferrous sulfate heptahydrate (132 g) and tartaric acid (40 g) in water (400 mL) at 0 ~C. The mixture was stirred for 20 min, then transferred to a separatory funnel and extracted with t-BuOMe (2x200 mL). The combined organic phase was stirred with 30~ NaOH solution containing NaCl, for 1 h at 0~C. The layers were again separated, and the aqueous phase extracted with t-BuOMe. The combined organic phase was washed with brine, dried over MgS04 and concentrated to yield 52.8 g as an amber oil.

Step 4. (2R, 3R)-2-hydroxy-3-methyl-5-phenylpentan-1-ol .
To a 5L 3 neck round bottom flask equipped with a mechanical stirrer, thermocouple and nitrogen inlet was added hexanes (lL) and cooled to O C. A 2.OM solution of Me3Al in hexanes (800 mL, 1.6 mol) was added, followed by a solution of the epoxide (120 g, 0.677 mol) in hexanes (250 mL)/CH2Cl2 (50 mL) maintaining the temperature below 20~C. Upon complete addition, the cloudy reaction mixture was stirred at 5~C for 35 min, whereupon a solution of 10% HCl (300 mL) was added dropwise, followed by the addition of concd HCl (350 mL).
The layers were separated, and the organic phase was washed with brine and dried over MgS04. After removal of the volatiles in vacuo, 122.1 gram of an oil was obtained.

Step 5. (2R, 3R)-2-hydroxy-3-methyl-5-phenylpent-1-yl Tosylate. To a 2L 3 neck round bottom flask equipped with a mechanical stirrer and nitrogen inlet was added the diol ~58 g, 0.30 mol), dibutyltin oxide (1.5 g, 0.006 mol, 2 mol%), toluenesulfonyl chloride (57.5 g, 0.30 mol), CH2Cl2 (580 mL) and triethylamine (42.0 mL, 0.30 mol). The resulting mixture was stirred at room temperature for 2 h (although the reaction was complete within 1 h), filtered, washed with water and dried over MgS04. Concentration of the volatiles in vacuo afforded 104.1 gram of a slightly amber oil.

Step 6. (2R, 3~)-2-[(tert-Butyldimethylsilyl)oxy]-3-methyl-5-phenylpent-1-yl Tosylate. A solution of the tosylate (100 g, 0.29 mol) and triethylamine (81.0 mL, 0.58 mol) in CH2C12 (1200 m~) was treated with neat TBS-OTf (99 mL, 0.~3 mol) dropwise with continued stirring for another 20 min. The reaction was washed twice with brine, dried over MgS04 and concentrated to dryness. The oil was dissolved in a minimal amount of hexanes and filtered over a silica pad, eluting - W O 98/08506 PCTrUS97/15245 with hexanes:EtOAc (9:1) to yield a slightly amber oil, 134 g.

Step 7. (2R, 3R,5RS)-2-[(tert-Butyldimethylsilyl)oxy]-3-methyl-5-bromo-5-phenylpent-1-yl Tosylate. To a SL 3 neck round bottom flask equipped with a mechanical stirrer, reflux condenser and nitrogen inlet was added CCl4 (1680 mL), TBS Ts (140 g, 0.30 mol), NBS (65g, 0.365 mol) and AIBN
(16.5 g, 0.10 mol). The mixture was degassed by evacuation under full vacuum with stirring, and backfilling with nitrogen (3x~. The reaction mixture was then heated to reflux, whereupon the color became dark brown. After 15 min at vigorous reflux, the reaction mixture became light yellow, and chromatographic analysis indicated the reaction was complete. After cooling to room temperature, the reaction was filtered and the filtrate concentrated to dryness. The residue was redissolved in hexanes and filtered again, and concentrated to dryness to afford 170.3 gram as an amber oil.
Step 8. ~2R, 3R)-2-[ (tert-Butyldimethylsilyl)oxy]-3-methyl-5-phenylpent-4(E)-en-1-yl Tosylate. To a 2L 3 neck round bottom flask equipped with a mechanical stirrer, reflux condenser and nitrogen inlet was added a solution of the bromide ~100 g, 0.186 mol) in acetonitrile (700 mL). DBU
(83.6 mL, 0.557 mol) was added and the resulting dark brown solution was stirred at reflux for 15 min. After cooling to room temperature, the solvent was removed in vacuo, and the residue digested in CH2Cl2 (200 mL) and filtered through a silica pad. The volatiles were again evaporated, and the residue dissolved in EtOAc and washed with water, brine and dried over MgSO4 and concentrated to dryness. Preparative mplc (Prep 500) chromatography afforded the desired unsaturated compound (50.3 g, 60% yield over 4 steps).

- W O 98108506 PCTrUS97115245 Step 9. (3S, 4R)-3-~(tert-Butyldimethylsilyl)oxy]-4-methyl-6-phenylhex-5(E)-en-1-nitrile. The tosylate (50 g, 0.11 mol) was dissolved in DMSO (1 L) and treated with KCN (14.2 g, 0.22 mol) and water (25 mL~, and the resulting mixture was stirred at 60~C under nitrogen for 18 h. After cooling to room temperature, the reactlon mixture was partitioned between EtOAc (1 L) and water (1 L). The aqueous phase was extracted with EtOAc (500 mL), and the combined organic phase was washed with brine and dried over Na2SO4. Flash chromatography over silica with CH2C12 afforded the desired nitrile in 92% yield.

Step 10. Methyl (5S, 6R)-5-[(tert-Butyldimethylsilyl)oxy]-6-methyl-8-phenylocta-2 (E) ,7 (E) -dienoate. The nitrile (14.67 g, ~6.5 mmol) was dissolved in toluene (200 mL) and cooled to -78~C under nitrogen. A 1.5M solution of DIBAL in toluene (37.2 mL, 55.8 mmol) was added dropwise with vigorous stirring. Upon complete addition, the cooling bath was removed and the reaction was stirred at room temperature for 1 h. The reaction mixture was carefully poured into lN
HCl and the mixture stirred at room temperature for 30 min.
The layers were separated, and the organic phase was washed with a saturated aqueous solution of sodium potassium tartrate (2x), brine and dried over Na2SO4. The volatiles were removed in vacuo, and the crude pale yellow oil was used directly in the subsequent condensation. The crude aldehyde from above was dissolved in THF (90 mL) and treated with trimethyl phosphonoacetate (9.03 mL, 55.8 mmol) and tetramethylguanidine (7.0 mL, 55.8 mmol) at room temperature under nitrogen. The reaction mixture was stirred for 16 h, then partitioned between EtOAc (200 mL) and water (100 mL).
The aqueous phase was back extracted with EtOAc (100 mL), and the combined organic phase was washed with water, brine and dried over Na2SO4. The volatiles were removed in vacuo, and the crude yellow oil (17.0 g) was chromatographed over CA 02263420 1999-02-ll - W O 98/08506 PCTrUS97/1524S

silica gel with CH2C12 ~ cyclohexane (1 : 1 to 2 : 1) to afford 13.67 grams of the desired ester, 78.5%.

Preparation 2 ~o Methyl ester (2.673 mmol) was dissolved in acetone and then lN aqueous LiOH (26m~) added at room temperature. The cloudy mixture was further diluted with acetone (20mL) and the resulting yellow mixture stirred at room temperature for 23.5h. The reaction was diluted with diethylether (400mL) and the organics washed with lN HCl (120mL), brine (200mL) and H2O ~160mL). The organics were dried and concentrated in vacuo to leave a yellow oil which was purified by column chromatography (gradient: 5% AcOH + 20%-40% EtOAc/Hexanes ) to give carboxylic acid as a yellow oil (960mg, 100%).
1H NMR (CDC13) d 7.38-7.19 (m,PhHs), 7.09 (ddd,J=15.2,7.6 and7.9 Hz,3-H), 6.38 (d,J=16 Hz,8-H), 6.16 (dd,J=16 and8 Hz, 7-H), 5.85 (d,J=15.8Hz,2-H),3.81-3.75 (m,5-H), 2.49-2.37 (m,6-H,4-CH2), 1.12 (d,J=6.7Hz,6-Me), 0.91 (s,SiCMe3), 0.065 (s,SiMe), 0.068 (s,SiMe) ppm;
IR u (CHC13) 2957,2930,2858,1697,1258,1098,838 cm~l;
MS (FD) 360.2 (M+,100);
[a]D+87.6~ (c 10.5, CHC13);
Anal. calcd. for C2lH32O3 requires: C,69.95; H,8.95%. Found:
C,69.19; H,8.39%.

- W O 98/08506 PCT~US97115245 Preparation 3 CH~
~,J~ ~, o ~ OTBS O -N ~

To a stirred solution of carboxylic acid (2mmol) in dry dimethylformamide t5 50mL) was added 1-ethyl-3-(3-dimethyaminopropyl)carbodiimide (2.4mmol) and N-hydroxysuccinimide (2.6mmol) at room temperature. The mixture was stirred for 28h and then diluted with EtOAc (lOOmL) and washed with lN aqueous HCl (2x50mL), H2O (75mL), dried and concentrated in vacuo to leave an oil. Crude product was purified by column chromatography (gradient: 5-30% EtOAc/Hexanes) to give active ester as a pale yellow oil (724mg,80%).
1H NMR (CDCl3) d 7.36-7.20 (m,PhHs,3-H), 6.38 (d,J=16Hz,8-H), 6.14 (dd,J=16.1 and 8.0 Hz,7-H). 6.03 (d,J=16Hz,2-H), 3.79 (q,J=4.3Hz,5-H), 2.94 (brs,CH2CH2), 2.58-2.42 (m,6-H,4-CH2), 1.10 (d,J=6.8Hz,6-Me), 0.90 (s,SiCMe3), 0.05 (s,SiMe2) ppm;
IR u (CHCl3) 2957,2931,2858,1772,1741,1648,1364,1254,1092,1069,838 cm~1;
MS (FD) 457 (M+,100);
[a] D +71.3~ (c 10.1, CHCl3);
Anal. calcd. for C2sH3sNOs requires: C,65.61;H,7.71,N,3.06%.
Found: C,65.51;H,7.56; N, 3.02%.

.

- W O 98/08506 PCTrUS9711524S

Preparation 4 To a stirred solution of silyl ether (2.50g,5.47mmol) in CH3CN (13OmL) was added 48% aqueous HF (15mL) at 0~C. The solution was stirred at 0~C for 0.75h and then at room temperature for 4h. The reaction was diluted with diethylether (300mL) and washed with H2O until the wash was ~pH7. Organics were dried (MgSO4) and concentrated in vacuo to give a yellow residue which was recrystallized from Et20 to give alcohol as white crystals (1.46g,78%).
lH NMR (CDCl3) d 7.41-7.20 (m,PhHs,3-H), 6.48 (d,J=16Hz,8-H), 6.15-6.07 (m,7-H,2-H), 3.71-3.65 (m,5-H), 2.83 (brs,CH2CH2), 2.60-2.33 (m,6-H,4-CH2),1.95 (brs, 5-OH), 1.14 (d,J=6.8Hz,6-Me) ppm;
IR u (KBr) 3457,1804,1773,1735,1724,1209,1099,1067,1049,975,744,694 cm~
l;
W (EtOH) lmaX 250 (e =20535) nm;
MS (FD) 343.2 (M+,100);
[a] D -57.8~ (c 10.56, CHCl3);
Anal. calcd. for ClgH21NOsS requires: C,66.46;H,6.16;N,4.08%.
Found: C,66.49; H,6.16; N, 4.07%.

- W O 98/08506 PCT~US97/1524S

Example 1 0"~'~
~ O O
O ~ NHBoc C

To a suspension of carboxylic acid (1.28g, 3.87mmol), in dry dichloromethane (6mL) was added EDC ~742mg,3.87mmol) and DMAP (73mg,0.60mmol) and the mixture stirred at room temperature for 0.5h. A solution of alcohol (1.02g, 2.97mmol) in dichlormethane (5.5mL) was added to the reaction mixture and stirred for a further 0.3h.The reaction was diluted with CH2Cl2 (200mL) and washed with lN aq. HCl (2x 50mL), sat. aq. NaHCO3 (2x 50mL), H20 (50mL). The organics were dried (MgSO4) and concentrated in vacuo to leave an oily residue, which was purified by column chromatography (gradient: 10-30'~ EtOAc/Hexanes) to give the desired ester as a yellow solid (1.68g,79%).
H NMR (CDCl3) unit A d 7.35-7.20 (m,PhHs,3-H), 6.43 (d,J=15.8Hz,8-H), 6.12 (d,J=15.9Hz,2H), 5.99 (dd,J=8.5 andl5.8 Hz,7-H), 5.06-5.08 (m,5-H), 2.85 (brs,CH2CH2), 2.68-2.61 (m,6-H,4-CH2), 1.13 (d,J=6.8Hz,6-Me)i unit C d 5.31 (brt,NH),3.28-3.25 (m,3-CH2),1.43 (s,CMe3), 1.21 (s,2-Me), 1.19 (s,2-Me); unit D d 4.95 (dd,J=9.8 and 3.8Hz,2-H), 1.73-1.64 (m,3-H,4-H), 1.59-1.49 (m,3-H'), 0.85 (d,J=6.4Hz,5-Me), 0.82 (d,J=6.4,4-Me) ppm;
IR u (KBr) 3900, 2975,1743,1367,1206,1126,1145,1068 cm~1;
MS (FD) 657 (M+,100);
[a]D+39.5~ (c 10.38, CHCl3)i Anal. calcd. for C3sH48N2Olo requires:
C,64.01iH,7.37;N,4.27%. Found: C,64.19jH,7.27; N,4.52 %.

., ~ .. ~

Example 2 A

~ O C02H
12 ~ OJ~NHBoc J~ ~

To a stirred solution of active ester (150mg, 0.229mmol) in dry DMF (2.5mL) was added N,O-Bis-(trimethylsilyl)acetamide (282uL,1.143mmol) followed by D-Hydroxy-phenylglycine (57mg,0.343mmmol). The mixture was heated in a sealed tube under N2 at 55 C for 20h. Reaction solution was diluted with EtOAc (180mL) and washed with lN aq. HCl (50mL),H20 (50mL), brine (50mL), dried (MgSO4) and concentrated in vacuo to give a yellow solid. Purification of the crude solid by column chromatography (gradient: 5-20% MeOH/CH2Cl2) provided amide (122mg,75~).
lH NMR (CD30D/CDC13) Unit A d 7.27-7.20 (m,PhHs), 6.75-6.69 (m,3-H), 6.43 (d,J=15.9Hz,8-H), 5.96 (d,J=15.7Hz,7-H), 5.93 (d,J=15.6Hz,2-H), 4.95-4.93 (m,5-H), 2.56-2.49 (m,6-H,4-CH2), 1.04 (d,J=6.8Hz,6-Me); Unit B d 7.16 (d,J=8.3Hz,ArH2), 6.66 (d,J=8.2Hz,ArH2), 5.62 (brt,NH)5.19-5.18 (m,2-H); Unit C d 3.15 (d,J=6.3Hz,3-CH2), 1.36 (s,CMe3), 1.11 (s,2-Me), 1.08 (s,2-Me); Unit D d 4.85 (dd,J=9.6 and 3.3Hz,2-H), 1.64-1.57 (m,3-H,4-H), 1.55-1.47 (m,3-H'), 0.76 (d, J=6.3Hz,5-Me), 0.73 (d,J=6.3Hz,4-Me) ppm ;

IR u (KBr) 3400,2972,1728,1672,1614,1515,1450,1416,1171,1147 cm-l;
MS (FAB) 610.6 ([MH2-Boc]+,100);
[a] D -19.9~ (C 6.53, MeOH).

Example 3 - W O 98108506 PCTrUS97/15245 ~p,OH
r~ HN X~

D ~OJ~N ~

c Boc amine as prepared by Example 2 (109mg,0.154mmol) was dissolved in trfluoracetic acid (5mL,5mM) and stirred at room temperature for 2h.The reaction was concentrated in vacuo and dried under high vacuum to give the trifluoroacetate salt of amine as a light brown foam. Crude amine salt (max. 0.154mmol) was dissolved in dry DMF (31mL) and diisopropylethylamine (80uL,0.462mmol), followed by pentafluorophenyl diphenyl -phosphinate (77mg,0.2mmol) added. The resulting solution was stirred at room temperature under dry N2 for 15h, concentrated in vacuo and the residue purified by column chromatography (gradient: 1-4% MeOH/CH2Cl2) to provide cryptophycin as a tan solid (54mg,59%).
1H NMR (CDCl3) Unit A d 7.36-7.15 (m,PhHs), 6.79-6.69 (m,3-H), 6.54 (d,J=15.8,8-H), 5.98 (dd,J= 15.8 and 8.8 Hz,7-H), 5.06-5.0 (m,5-H), 2.61-2.49 (m,6-H,4-H), 2.39-2.30 (m,3-H'), 1.10 (d,J=6.8Hz,6-Me); Unit B d 7.90 (dd,J=10 and 1.68Hz,OH), 7.65 (d,J=6.3Hz,NH), 7.10 (d,J=8.5,ArH2), 6.71 (d,J=8.4,ArH2), 5.28 (d,J=6.5Hz,2-H), ; Unit C d 3.55-3.47 (dd,J=13.3 and lO.lHz,3-CH2), 3.00 (d,J=13.4Hz,NH) 1.19 (s,2-Me), 1.16 (s,2-Me); Unit D d 4.90 (dd,J=10 and 3.5Hz,2-H), 1.66-1.54 (m,3-H,4-H), 1.32-1.25 (m,3-H'), 0.67 (apparent t,J=7.lHz,5-Me,4-Me) ppm;
IR u (KBr) 3418,3340,2960,1740,1713,16711514,1271,1198,1155,972 cm~1;
MS (FD) 590 (M+,100);
[a]D+15.35~ (c 3.91, CHCl3).

..... ,.. ~. , i W O 98/08506 PCT~US97/15245 Example 4 A

~OH

J~OJ~N ~

Styrene prepared as described by Example 3 (42mg, 0.0712mmol) was suspended in dry dichloromethane (2.2mL, 0.035mM) and mCPBA (49mg, 0.285mmol) added in one portion at room temperature. Dry tetrahydrofuran (0.3mL) was added to produce a homogeneous solution. The reaction was stirred under N2 at room temperture for 21h and then diluted with further CH2Cl2 (15mL). Organics were washed with 10% aq.
Na2S20s (lOmL), sat. aq. NaHCO3 (lOmL), H20 (lOmL), dried (MgSOg) and concentrated in vacuo to give a yellow solid.
Crude product was initially purified by column chromatography (gradient: 1-5% MeOH/ CH2Cl2) to give a 1:
1.15 mixture of a:b C7-C8 epoxides as a white solid (23mg, 54~).Reverse phase HPLC (column: 4.6x250mm Kromsil C18;
Eluent: 60% CH3CN/ H20; Flow: l.OmL/min; W: 220nm) separation of the a:b mixture provided a-epoxide (2.3mg, t=13.7min~ and b-epoxide (5.8mg, t=12.lmin) as white solids.

- W O 98/08506 PCTrUS97/lS245 - Example 5 ~~~ 1"'~ iL

~O J~ N O
C

The above illustrated compound was prepared substantially as described above using the procedures of Examples 1-4 a-Epoxide:
1H NMR (CDCl3) Example 6 A

,OH

~OJ~N O
C

The above illustrated compound was prepared substantially as described above using the procedures of Examples 1-4 b-Epoxide:
1H NMR (CDCl3) Unit A d 7.36-716 (m,PhHs), 6.70-6.79 ~m,3-H), 5.91 (dd,J=15.5 and 5.18Hz,2-H) 5.23-5.18 (m,5-H), 3.75 (d,J=1.67Hz,8-H), 2.96 (dd,J=7.4 and 2.OHz,7-H), 2.72-2.67 (m,4-H), 2.44-2.39 (m,4-H'), 1.81-1.88 (m,6-H), 1.13 (d,J=6.9,6-Me); Unit B d 7.66 (s,NH), 7.13 (d,J=8.5Hz,ArH2), 6.74 (d,J=8.5Hz,ArH2), 5.27 (s,2-H); Unit C d 7.66 (s,NH), CA 02263420 1999-02-ll 3.49 (dd,J=13. 6 and lOHz,3-CH2), 1.20 (s,2-Me),1.18 (s,2-Me); Unit D d 4.93 (dd,J=10 and 3.2Hz,2-H), 1.69-1.59 (m,3-H,4-H), 1.30-1.22 (m,3-H'), 0.79 (d,J=6.2Hz,5-Me), 0.78 (d, J=6. 3Hz,4-Me) ppm.

CA 02263420 1999-02-ll - W O 98l08506 pcTrus97ll5245 Exaunple 7 CN~COOHNH ~COOH
1 ' 2' C~~H2~--NH2 C~~H2~H
o o 2' t 3 o C~ r~
Cl + 0~,0 NH~ ~OCH3 O~,O o NH~,..~OCH3 $o~ .CF3COOH ~ CNH/~HcoocH2ccl3 3' 4' t 5' r~ Cl r~ Cl Oq~O O NH~,.~oCH3 Oq~O o NH~,..''~oCH3 "~N'~HCOOCH2CC13 ,~NJ~NH2cooH
+

5' 6' ~ r~ cl ~1 r~
Oq~O O NH~ ~oCH3 ~q~~ o NH~ ~oCH3 ~-~N~NHCOOH ~NJ~NH o .CF3COO H
6' 7' ~ o Cl ~l~ ~'rO Cl o~,o O NH~ ~OCH3 ~q~~ o NHl ~oCH3 ,~NHJ~NH o . ,~HN~NH o 7' 8' . ~.

'- W 098/08506 rCTtUS97tlS245 _ 2 ~
1" 2"

2 ~ ~ ~H

2" ~ 3"' Ar~ r~ A /~ -l~ o CO + O~,X NH~I/R6 O~,X o NH~ R6 ~ 2~H,"~NH COOCH2CCI3 . ,,cNJ~N~H COOCH2CC13 1~ .CF3COOH o ~
t 3" Jr 5"

Ar r~ A ' ~~~'r~
Oq~X Q NH~ R6 o~,,x Q NH~ R6 HCOOCH2CCI3 ,~NJ~NH2 CF COOH

t 5............................ 6"
Ar'~- ~ r~ Ar r~
Oq~X ~ NH~I R6 O~,X o NH~--R6 ~NH2 "~H J~

6" 7"
CIOH I
Ar~ O A ~IJ\' r~
O~,,X o NH~ R6 ~~ ,X o NH R6 R~HNJ~NH o ~ R9R1l 'NJ~N H Xo 7" 8"

- W O 98/08506 PCTrUS97/15245 To a 500 ml Parr hydrogenator bottle were charged 3.0 g (27 ~ mmol) of 1-cyano-1-cyclopropanecarboxylic acid 1' (Aldrich) and 1.0 g of platinum (IV) oxide in 250 mL of glacial acetic acid. The mixture was hydrogenated at 60 psi hydrogen for 4 h. After filtering away the catalyst, the volatiles were removed in vacuo and the solid was dried in a vacuum oven at 75~ C. This solid was then triturated in CHCl3, filtered and dried to give 2.7 g (86%) of 2' (LY257141) as a white solid.

m.p.= 261-262~ C (foam, dec) Mass (FD) M+1 = 116 To a 250 mL 24/40 round bottom flask were charged 1.5 g (13.0 ~nmol) of 2' (LY257141) dissolved in 28 mL of 1,4-dioxane, 15 mL water, and 15 mL of 2N NaOH. The solution was then cooled down in an ice bath, followed by the slow addition of 3.3 mL (14.3 mmol) of di-t-butyl dicarbonate.
The reaction was stirred at RT for 21 h. The 1,4-dioxane was removed in vacuo and the aqueous was diluted with additional water and layered with EtOAc The pH of the stirring solution was adjusted to 3 using 0.5 N NaHSO4. The organic layer was separated away, and the aqueous was extracted with EtOAc. The organic layers were combined, washed with brine, dried, over Na2SO4, filtered and removed in vacuo to give 2.6 g (93%) of 3' (LY382186) as a white solid.

m.p.= 104-106~ C

MASS (FD) M+1 - 216 ., . , .. , ,, . ~ , CA 02263420 1999-02-ll A~ter flame drying a 100 mL 14/20 3-neck round bottom flask under a nitrogen atmosphere, were charged 0.81 g (3.8 mmol) of 3' dissolved in 10 mL of anhydrous THF, followed by the addition of 0.80 g ~4~2 mmol~ of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide and 0.64 g (4.75 mmol) of 1-hydroxybenzotriazole. Next, 10 mL of anhydrous DMF were added and a solution resulted. To this solution was then added 1.35 g (1.65 mmol) of 4' (LY384785) and 0.31 mL (2.85 mmol) of 4-methylmorpholine dissolved in 5 mL of anhydrous DMF. The reaction was stirred at RT for 2 h. The volatiles were removed in vacuo, and the residue was dissolved in EtOAc and washed with 0.1 N HCl, brine, dried over Na2SO4, and removed in vacuo. This crude solid was purified on silica gel using flash chromatography, eluting with 20%
EtOAc/Hex to give 1.14 g (77%) of 5' (LY396076) as a white solid.

m.p.= 73-75~ C

Mass (FD) M+1 = 900 To a 250 mL round bottom flask were charged 1.1 g (1.22 mmol) of 5' (LY396076) and 4.0 g of zinc dust. The mixture was sonicated for 45 min and then stirred at RT for an 25 additional 45 min. The reaction was filtered through celite, washed with fresh HOAc and MeCl2, and the filtrate was removed in vacuo and pumped dry. This white solid was then dissolved in 40 mL of trifluoroacetic acid and stirred at RT for 2 h. The TFA was removed in vacuo, and this crude 30 residue was purified on silica gel using flash chromatography, eluting with 20% MeOH/CHCl3 to give 0.77 g (81%) of 6' (LY396077) as a white solid.

CA 02263420 1999-02-ll W 0 98/08506 PCTrUS97/15245 m.p.= 131-134~ C
-Mass (FD) M+ = 668 To a flame dried 250 mL 14/20 round bottom flask under a nitrogen atmosphere were charged 0.76 g (0.97 mmol) of 6 (LY396077) and 1.02 mL (5.83 mmol) of anhydrous N,N-diisopropylethylamine in 125 mL of anhydrous DMF. Then 0.48 g (1.26 mmol) of pentafluorophenyl diphenylphosphinate was dissolved in 18 mL of anhydrous DMF and added dropwise to the solution and the reaction was stirred at RT for 4 h.
The DMF was removed in vacuo, and the residue was dissolved in CHCl3 and washed with water, brine, dried over NaSO4, and removed in vacuo. The crude residue was purified on silica gel using flash chromatography, eluting with 100% EtOAc to give 0.52 g (82%) of 7' (LY396078) as a white solid.

m.p.= 114-117~ C

Mass (FD) M+ = 650 After flame drying a 15 mL 14/20 round bottom flask under a nitrogen atmosphere, 0.49 g (0.75 mmol) of 7' (LY396078) was dissolved in 5 mL of anhydrous MeCl2. Next, 0.14 g (0.79 mmol) of purified 3-chloroperbenzoic acid was added and the reaction was stirred at RT for 23 h. The reaction was diluted with some additional MeCl2, and washed with 10%
Na2S2O5, brine, 5% NaHCO3, brine, dried over NaSO4, and removed in vacuo to give 0.45 g (90%) of a crude white solid as a mixture of the a and ~ epoxides. This solid was then reacted directly without further purification. To a 50 ml 14/20 round bottom flask was dissolved 0.43 g (0.675 mmol) of the isolated epoxide mixture in 13 mL of anhydrous CHCl3.

. . .

CA 02263420 1999-02-ll The solution was cooled down in an ice bath, followed by the ~addition of 0.34 mL (2.7 mmol) of chlorotrimethylsilane.
The ice bath was then removed, and the reaction was stirred at RT for 2.5 h. The volatiles were removed in vacuo, and the crude residue was purified on silica gel using flash chromatography, eluting with 1% MeOH/EtOAc to give 0.16 g (34%) of the ~-chlorohydrin 8' as a white solid.

m.p.= 159-162~ C
Mass (FD) M+ = 702

Claims (44)

Claims

1. The presently claimed invention provides novel compounds of Formula I
wherein Ar is phenyl or any simple unsubstituted or substituted aromatic or heteroaromatic group, C1 C12 alkyl, C1-C12 alkyne;
R' is halogen, OH, OR31, SH, amino, monoalkylamino, dialkylamino, trialkylammonium, alkylethio, dialkylsulfonium, sulfate, or phosphate;
R2 is OH, NH2, NR31, SH; or R1 and R2 may be taken together to form an epoxide ring, an aziridine ring, an episulfide ring, a sulfate ring, a cyclopropyl ring, or monoalkylphosphate ring; or R1 and R2 may be taken together to form a second bond between C18 and C19;
R31 is C1-C6 alkyl and hydrogen;
R3 is a lower alkyl group;
R4 is H;
R5 is H;
R4 and R5 may be taken together to form a second bond between C13 and Cl4;
R6 is a substituent selected from the group consisting of B-ring heteroaromatic, substituted heteroaromatic, B-ring (C1-C6)alkyl, (C3-C8) cycloalkyl, substituted C3-C8 cycloalkyl, substituted (Cl-C6)alkyl, a group of the formula III':

and a group of the formula III'':

R7 is selected from the group consisting of NR51R52, R53NR51R52, OR53, H and a lower alkyl group; R51 and R52 are independently selected from the group consisting of C1-C3 alkyl; R53 is Cl-C3 alkyl;
R8 is H or a lower alkyl group;
R7 and R8 can optionally form a cyclopropyl ring;
R9 is selected from the group consisting of H, a lower alkyl group, unsaturated lower alkyl, and lower alkyl-C3-C5 cycloalkyl;
R10 is H or a lower alkyl group;
R9 and R10 together optionally form a cyclopropyl ring;
R11 is selected from the group consisting of H, OH, simple alkyl, phenyl, substituted phenyl, benzyl, and substituted benzyl;
R14 is H or a lower alkyl group;
R15, R16 and R17 are each independently selected from the group consisting of hydrogen, (C1-C6)alkyl, OR18, halo, NR18R19, NO2, OPO3H2, OR19phenyl, SCH2phenyl, CONH2, CO2H, PO3H2, and SO2R23, and ZZ;
R18 is selected from the group consisting of hydrogen, aryl, and C1-C6 alkyl;
R18 is selected from the group consisting of hydrogen and (C1-C6)alkyl;

R19 is C1 -C6 alkyl;
R19 is selected from the group consisting of hydrogen and (C1-C6)alkyl R23 is selected from the group consisting of hydrogen and (C1-C3)alkyl;
R29 iS (C1-C5) alkyl;
R30 is hydrogen or C1 -C6 alkyl;
n is 0, 1, or 2;
p is 0, 1, or 2;
m is 0, 1, or 2;
X is selected from the group consisting of O, NH and alkylamino;
Y is selected from the group consisting of O, NH, and alkylamino;
Z is selected from the group consisting of -(CH2)n~/ -(CH2)p-O-(CH2)m- and (C3-C5) cycloalkyl;
ZZ is selected from the group consisting of an aromatic group and a substituted aromatic group; or a pharmaceutically acceptable salt or solvate thereof;
provided that when R6 is a group of Formula III' and n is 1, then at least one of the group consisting of R15, R16 and R17 must be a non-hydrogen group and if only one of R15, R16 and R17 is OH or OR29 and one of the group consisting of R15, r16 and R17is halo then the remaining member of the group consisting of R15, R16, and R17 must not be hydrogen or halo;
or when R6 is a group of Formula III' and n is 1, Rl4 is a lower alkyl group.

2. A compound of Claim 1 wherein Y is O.

3. A compound of Claim 2 wherein X is O.

4. A compound of Claim 3 wherein R6 is a group of the formula:

5. A compound of Claim 4 wherein R9 is isobutyl and R10 is hydrogen.

6. A compound of Claim 5 wherein R8 and R7 are each independently selected from the group consisting of methyl and hydrogen.

7. A compound of Claim 6 wherein R1 and R2 form an epoxide group.

8. A compound of Claim 1 wherein none of R15 R16 and R17 are C1-C3 alkyl.

9. A compound of Claim 8 wherein X is 0.

10. A compound of Claim 9 wherein R6 is a group of the formula:

11. A compound of Claim 10 wherein R8 and R7 are each methyl.

12. A compound of the Formula I' wherein Ar is phenyl or any simple unsubstituted or substituted aromatic or heteroaromatic group, C1-C12 alkyl, C1-C12 alkyne;
R' is halogen, OH, OR31, SH, amino, monoalkylamino, dialkylamino, trialkylammonium, alkylthio, dialkylsulfonium, sulfate, or phosphate;
R2 is OH, NH2, NR31, SH; or R31 is C1-C6 alkyl and hydrogen;
R1 and R2 may be taken together to form an epoxide ring, an aziridine ring, an episulfide ring, a sulfate ring, a cyclopropyl ring, or monoalkylphosphate ring; or R1 and R2 may be taken together to form a second bond between C18 and C19;
R3 is a lower alkyl group;
R4 is H;
R5 is H;
R4 and R5 may be taken together to form a second bond between C13 and C14;
R6 is a substituent selected from the group consisting of B-ring heteroaromatic, substituted heteroaromatic, B-ring (C1-C6) alkyl, (C3-C3) cycloalkyl, substituted C3-C8 cycloalkyl, substituted (C1-C6) alkyl, a group of the formula III':

and a group of the formula III'':

R7 is selected from the group consisting of H and a lower alkyl group;
R8 is H or a lower alkyl group;
R7 and R8 can optionally form a cyclopropyl ring;
R9 is selected from the group consisting of H, a lower alkyl group, unsaturated lower alkyl, and lower alkyl-C3-C5 cycloalkyl;
R10 is H or a lower alkyl group;

R50 is hydrogen or R11 is selected from the group consisting of H, OH, simple alkyl, phenyl, substituted phenyl, benzyl, and substituted benzyl;
R14 is H or a lower alkyl group;
R15, Rl6, and R17 are each independently selected from the group consisting of hydrogen, (C1-C6)alkyl, OR18, halo, NR18R19, NO2, OPO3H2, OR19phenyl, SCH2phenyl, CONH2, CO2H, PO3H2, and So2R23, and ZZ;
R18 is selected from the group consisting of hydrogen, aryl, and C1-C6 alkyl;
R18 is selected from the group consisting of hydrogen and (C1-C6)alkyl;

R39 is C1-C6 alkyl;
R19 is selected from the group consisting of hydrogen and (C1-C6)alkyl;
R23 is selected from the group consisting of hydrogen and (C1-C3) alkyl;
R29 is (Cl-C5)alkyl;
R30 is hydrogen or C1-C6 alkyl;

R is hydrogen or a group of the formula n is 0, 1, or 2;
p is 0, 1, or 2;
m is 0, 1, or 2;
X is selected from the group consisting of O, NH and alkylamino;
Y is selected from the group consisting of O, NH, and alkylamino;
Z is selected from the group consisting of -(CH2) n~, - (CH2)p-O-(CH2)m- and (C3-C5)cycloalkyl;
ZZ is selected from the group consisting of an aromatic group and a substituted aromatic group; or a pharmaceutically acceptable salt or solvate thereof;
provided that when R6 is a group of Formula III' and n is 1, then at least one of the group consisting of R15, R16 and R17 must be a non-hydrogen group and if only one of R15, R16 and R17 is OH or oR29 and one of the group consisting of R15, R16 and R17 is halo then the remaining member of the group consisting of R15, R16 and R17 must not be hydrogen or halo;
or when R6 is a group of Formula III' and n is 1 then R14 is lower alkyli further provided that the compound is not a crytophycin selected from the group consisting of cryptophycins:

13. A compound of Claim 12 wherein Y is O.

14. A compound of Claim 12 wherein X is O.

15. A compound of Claim 14 wherein R6 is a group of the formula:

16. A compound of Claim 15 wherein R9 is isobutyl and R10 is hydrogen.

17. A compound of Claim 16 wherein R8 and R7 are each independently selected from the group consisting of methyl and hydrogen.

18. A compound of Claim 17 wherein R1 and R2 form an epoxide group.

19. A compound of Claim 12 wherein none of R15, R16, and R17 are C1-C3 alkyl.

20. A compound of Claim 19 wherein X is O.

21. A compound of Claim 20 wherein R6 is a group of the formula:

22. A compound of Claim 21 wherein R8 and R7 are each methyl.

23. A compound of Claim 22 wherein R9 is isobutyl and R10 is hydrogen.

24. A compound of Claim 23 wherein R1 and R2 form an epoxide group.

25. A compound of Claim 12 wherein n is O.

26. A compound of Claim 12 wherein none of the group consisting of R15, R16 and R17 is halo or OCH3.

27. A compound of Claim 26 wherein n is O.

28. A compound of Claim 26 wherein n is 2.

29. A compound of Claim 26 wherein n is 1.

30. A compound of Claim 14 wherein R30 is methyl.

31. A compound of Claim 29 wherein R30 is hydrogen.

32. A compound of Claim 13 wherein R6 is selected from:

and ;

33. A compound of Claim 12 wherein R6 is selected from the group consisting of the following eight heteroaromatics:

34. A method for disrupting microtubule binding in a mammal comprising administering an effective amount of a compound of Claim 1.

35. A method for disrupting microtubule binding in vitro comprising administering an effective amount of a compound of Claim 1.

36. A method for treating a neoplasm in a mammal comprising administering an effective amount of a compound of Claim 1 to a patient in need thereof.

37. A formulation comprising a compound of Claim 1 and one or more pharmaceutically acceptable diluents or carriers therefor.

38. A method for treating a mammal suffering from or susceptible to a fungal infection, comprising administering an effective amount of a compound of Claim 1.

39. A method for disrupting microtubule binding in a mammal comprising administering an effective amount of a compound of Claim 11.

40. A method for disrupting microtubule binding in vitro comprising administering an effective amount of a compound of Claim 11.

41. A method for treating a neoplasm in a mammal comprising administering an effective amount of a compound of Claim 11 to a patient in need thereof.

42. A formulation comprising a compound of Claim 11 and one or more pharmaceutically acceptable diluents or carriers therefor.

43. A method for treating a mammal suffering from or susceptible to a fungal infection, comprising administering an effective amount of a compound of Claim 11.

44. A compound of Claim 11 wherein R6 is selected from the group consisting of , , , , , , and .